Literature DB >> 25621701

A feasible approach to evaluate the relative reactivity of NHS-ester activated group with primary amine-derivatized DNA analogue and non-derivatized impurity.

Shuping Dou1, John Virostko, Dale L Greiner, Alvin C Powers, Guozheng Liu.   

Abstract

Synthetic DNA analogues with improved stability are widely used in life science. The 3'and/or 5' equivalent terminuses are often derivatized by attaching an active group for further modification, but a certain amount of non-derivatized impurity often remains. It is important to know to what extent the impurity would influence further modification. The reaction of an NHS ester with primary amine is one of the most widely used options to modify DNA analogues. In this short communication, a 3'-(NH2-biotin)-derivatized morpholino DNA analogue (MORF) was utilized as the model derivatized DNA analogue. Inclusion of a biotin concomitant with the primary amine at the 3'-terminus allows for the use of streptavidin to discriminate between the products from the derivatized MORF and non-derivatized MORF impurity. To detect the MORF reaction with NHS ester, S-acetyl NHS-MAG3 was conjugated to the DNA analogue for labeling with (99m)Tc, a widely used nuclide in the clinic. It was found that the non-derivatized MORF also reacted with the S-acetyl NHS-MAG3. Radiolabeling of the product yielded an equally high labeling efficiency. Nevertheless, streptavidin binding indicated that under the conditions of this investigation, the non-derivatized MORF was five times less reactive than the amine-derivatized MORF.

Entities:  

Keywords:  Chelator; DNA analogues; conjugation; radiolabeling

Mesh:

Substances:

Year:  2015        PMID: 25621701      PMCID: PMC4398971          DOI: 10.1080/15257770.2014.958236

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  19 in total

1.  Preorganization of DNA: Design Principles for Improving Nucleic Acid Recognition by Synthetic Oligonucleotides.

Authors:  Eric T. Kool
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

Review 2.  DNA as supramolecular scaffold for functional molecules: progress in DNA nanotechnology.

Authors:  Thomas J Bandy; Ashley Brewer; Jonathan R Burns; Gabriella Marth; Thaonguyen Nguyen; Eugen Stulz
Journal:  Chem Soc Rev       Date:  2010-08-09       Impact factor: 54.564

Review 3.  Pharmacokinetic considerations in the development of oligomers as radiopharmaceuticals.

Authors:  D J Hnatowich
Journal:  Q J Nucl Med       Date:  1997-06

4.  Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.

Authors:  Guozheng Liu; Shuping Dou; Jiang He; Dongguang Yin; Suresh Gupta; Surong Zhang; Yi Wang; Mary Rusckowski; Donald J Hnatowich
Journal:  Appl Radiat Isot       Date:  2006-05-30       Impact factor: 1.513

Review 5.  Lipid conjugated oligonucleotides: a useful strategy for delivery.

Authors:  Mouna Raouane; Didier Desmaële; Giorgia Urbinati; Liliane Massaad-Massade; Patrick Couvreur
Journal:  Bioconjug Chem       Date:  2012-03-15       Impact factor: 4.774

6.  Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.

Authors:  Guozheng Liu; Kennedy Mang'era; Ning Liu; Suresh Gupta; Mary Rusckowski; Donald J Hnatowich
Journal:  J Nucl Med       Date:  2002-03       Impact factor: 10.057

7.  Improving the labeling of S-acetyl NHS-MAG(3)-conjugated morpholino oligomers.

Authors:  Guozheng Liu; Surong Zhang; Jiang He; Zhihong Zhu; Mary Rusckowski; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2002 Jul-Aug       Impact factor: 4.774

8.  The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice.

Authors:  G Liu; S Zhang; J He; N Liu; S Gupta; M Rusckowski; D J Hnatowich
Journal:  Q J Nucl Med       Date:  2002-09

9.  The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size.

Authors:  Guozheng Liu; Shuping Dou; Minmin Liang; Xiangji Chen; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Cancer       Date:  2009-10-05       Impact factor: 9.162

10.  Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.

Authors:  Guozheng Liu; Jiang He; Shuping Dou; Suresh Gupta; Jean-Luc Vanderheyden; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-23       Impact factor: 9.236

View more
  1 in total

1.  Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.

Authors:  Shuping Dou; John Virostko; Dale L Greiner; Alvin C Powers; Guozheng Liu
Journal:  Mol Pharm       Date:  2015-07-08       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.